ESO Lymphoma Course
A

Current and Future Drug Development in DLBCL: Review of Methodology, Failure History & New Trial Design

By ESO Lymphoma Course FEATURING Anastasios Stathis
September 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

10:37
Amgen Oncology

Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse

Feat. J. Abbas

Related Content

AUTOPLAY
Moffitt Cancer Center

16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Sat, Jan 18, 2020
The University of Kansas Cancer Center

KU ASH 2019 Review: Current Updates in Hematologic Diseases

Sat, Jan 18, 2020
13th ESO-EONS Masterclass in Oncology Nursing

13th ESO-EONS Masterclass in Oncology Nursing

Sat, Mar 21, 2020
8th ESO-SIOP Europe Masterclass in Paediatric Oncology

8th ESO-SIOP Europe Masterclass in Paediatric Oncology

Sat, Jun 6, 2020
Indy Hematology Review

17th Indy Hematology Review

Sat, Mar 21, 2020
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Fri, Feb 7, 2020
15:50
Indy Hematology Review

Treatment Algorithm for DLBCL

Feat. J. Leonard
17:49
Jonathan Friedberg

How to Improve on RCHOP for DLBCL: Role of Novel Agents

10:46
2018 Pan Pacific Lymphoma Conference

New Approaches to Initial treatment of DLBCL: R-CHOP +

Feat. N. Bartlett
15:30
2018 Pan Pacific Lymphoma Conference

Challenges of Treating HGBCL Patients with Comorbidities: Who is "FIT" f...

Feat. L. Sehn
19:22
2018 Pan Pacific Lymphoma Conference

Challenges of Treating HGBCL Patients with Comorbidities: Anthracyclines...

Feat. L. Sehn
22:17
ESO Lymphoma Course

First Line DLBCL: How Many Cycles of RCHOP? Improving Outcomes of CHOP: ...

Feat. A. Davies
12:47
2019 Scripps MD Anderson's Oncology Update

Lymphoma Practicing Changing ASCO19 Studies: Novel Agents Prior to R-Cho...

Feat. A. Saven
22:03
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Frontline Strategy for Aggressive Lymphoma - Can we Replace RCHOP?

Feat. J. Westin
16:44
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

How I Treat Double Hit Lymphoma

Feat. K. Dunleavy
17:51
2018 Pan Pacific Lymphoma Conference

Optimum Therapy for Standard Risk High Grade - DLBCL

Feat. N. Bartlett
28:21
John Pagel

Treatment of Newly Diagnosed DLBCL

10:10
Northwestern Medicine Oncology and Hematology

Treatment and Management Strategies for Diffuse Large B-cell Lymphoma Di...

Feat. L. Gordon
13:26
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

The Role of Venetoclax in DLBCL: Efficacy and Safety Results from the CA...

Feat. A. Zelenetz
07:09
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Next Questions in DLBCL: New Genetic Classification Based Selection of B...

Feat. A. Younes
18:20
ESO Lymphoma Course

Should We Add Other Agents Like Obinutuzumab, Lenalidomide, Bortezomib o...

Feat. A. Davies
25:29
2018 Pan Pacific Lymphoma Conference

How do we Incoporate PET-CT into Standard of Lymphoma Care and Research ...

Feat. B. Cheson
28:25
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Does RCHOP Stays the Standard of Care After 6 Cycles in Advanced/R DLBCL...

Feat. A. Younes
27:08
2018 Pan Pacific Lymphoma Conference

Clinical Trials for Patients with Lymphoma: How to Enroll More Patients?

Feat. J. Leonard
17:09
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

CD20-Based Bi-Specific Antibody Therapy in B-NHL: Mechanisms of Action, ...

Feat. M. Hutchings
22:43
ESO Lymphoma Course

R-CHOP Therapy for 61 y/o Male with Stage IIIB bulky DLBCL & Avoiding Ra...

Feat. A. Moccia